Table 3.
|
|
|
Discontinued regimens by reasonb |
|||
---|---|---|---|---|---|---|
Characteristic | Overall discontinueda | GI toxicity (N = 233) OR (95% CI) | Non-GI toxicity (N = 225) OR (95% CI) | Virologic failure/nonadherence (N = 172) OR (95% CI) | Loss to follow-up (N = 95) OR (95% CI) | Other (N = 301) OR (95% CI) |
Age (per 10 years) | 0.81 (0.71–0.93) | 0.97 (0.80–1.19) | 0.81 (0.68–0.97) | 0.81 (0.61–1.07) | 0.64 (0.50–0.81) | 0.75 (0.63–0.89) |
Female vs. male | 1.33 (1.03–1.73) | 1.58 (1.04–2.39) | 1.87 (1.32–2.64) | 1.09 (0.65–1.80) | 0.76 (0.44–1.32) | 1.16 (0.83–1.62) |
Black vs. white race | 1.28 (1.02–1.61) | 1.21 (0.84–1.74) | 1.13 (0.81–1.57) | 1.80 (1.20–2.70) | 1.31 (0.85–2.02) | 1.20 (0.89–1.62) |
Men who have sex with men (MSM) | 0.76 (0.61–0.96) | 0.73 (0.51–1.04) | 0.71 (0.51–0.99) | 0.76 (0.51–1.14) | 0.75 (0.49–1.16) | 0.84 (0.63–1.14) |
History of IV Drug use | 1.81 (1.22–2.66) | 2.57 (1.55–4.29) | 1.35 (0.81–2.25) | 2.37 (1.34–4.18) | 2.52 (1.32–4.83) | 1.09 (0.57–2.10) |
No insurance vs. private insurance | 1.51 (1.13–1.01) | 1.81 (1.12–2.93) | 1.45 (0.95–2.20) | 0.86 (0.51–1.47) | 2.07 (1.23–3.48) | 1.59 (1.11–2.28) |
Public insurance vs. private insurance | 1.73 (1.32–2.28) | 2.29 (1.54–3.41) | 1.38 (0.92–2.06) | 1.84 (1.16–2.92) | 1.53 (0.88–2.67) | 1.63 (1.10–2.39) |
Depression | 0.85 (0.67–1.08) | 1.22 (0.75–1.62) | 0.72 (0.46–1.13) | 0.99 (0.58–1.68) | 0.68 (0.42–1.11) | 0.68 (0.48–0.97) |
Substance abuse | 0.94 (0.71–1.24) | 1.10 (0.58–1.36) | 0.73 (0.45–1.17) | 0.87 (0.50–1.51) | 1.24 (0.71–2.15) | 0.86 (0.56–1.32) |
NNRTI | 0.86 (0.70–1.05) | 0.67 (0.49–0.93) | 1.27 (0.94–1.72) | 0.72 (0.51–1.01) | 1.29 (0.85–1.98) | 0.74 (0.56–0.99) |
PI | 1.25 (1.03–1.52) | 1.71 (1.26–2.34) | 1.03 (0.76–1.40) | 1.56 (1.10–2.22) | 0.89 (0.58–1.36) | 1.13 (0.86–1.50) |
HAART regimen number (range 1–12) | 1.14 (1.08–1.20) | 1.21 (1.13–1.29) | 1.10 (1.01–1.18) | 1.20 (1.09–1.31) | 0.96 (0.85–1.10) | 1.13 (1.06–1.21) |
Univariate logistic regression models accounting for dependent observations with active regimens as the reference group. Overall discontinued combines regimens stopped for GI toxicity, non-GI toxicity, virologic failure/nonadherence, and loss to follow-up.
Univariate multinomial logistic regression models accounting for dependent observations with active regimens as the reference group.